Notably, one study suggests that inhibiting IL-33 may halt the progression of non-alcoholic fatty liver disease to liver fibrosis and subsequently to hepatocellular carcinoma (HCC), highlighting its potential as a novel therapeutic target (106). Here, IL33 is linked to hepatocellular carcinoma.